Leadership and Members

Meet the leaders and members of the Leukemia Research program at the OSUCCC – James who work to develop targeted therapies for leukemia.

Lynne Abruzzo, MD, PhD

Dr. Abruzzo’s research focuses on the pathophysiology of chronic lymphocytic leukemia (CLL) and other low-grade B-cell leukemias and lymphomas. In particular, using classical cytogenetic and newer genomic technologies to identify prognostic markers in CLL, and to determine how to combine newly.

Read More

Leslie Andritsos, MD

Dr. Andritsos' research interests include: Chronic Lymphocytic Leukemia (CLL), bone marrow transplant

Read More

Robert Baiocchi, MD, PhD

Our laboratory program focuses on 3 major areas of research: (1) experimental therapeutics of lymphomas (epigenetics, antibodies, vaccine/immunotherapy); (2) mechanisms of Epstein-Barr virus driven B cell transformation; and (3) clinical research involving new methods to treat immune deficient

Read More

James Blachly, MD

Dr. Blachly's interest is in genomics and gene transcription in leukemia and its relevance in experimental therapeutics; namely, whether and how mutations and transcriptional attributes (including gene expression level, but also alternative splicing, alternative polyadenylation, , non-protein

Read More

Clara Bloomfield, MD

After serving as director of the OSU Comprehensive Cancer Center from 1997 to July 2003, Dr. Bloomfield became Senior Advisor to the OSU cancer program and the charter member of the OSU Cancer Scholars Program, which is designed to help recruit and retain senior cancer investigators of

Read More

Kristie Blum, MD

Dr. Blum's clinical research includes B-cell non-Hodgkins lymphoma, Hodgkin's lymphoma, Hairy cell leukemia, Waldenstrom’s macroglobulinemia and her research interests include Burkitt’s lymphoma, Mantle Cell Lymphoma, Diffuse large B-cell lymphoma, Hodgkin’s lymphoma

Read More

William Blum, MD

Dr. Blum's research interests include: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Other myeloid malignancies, Acute Lymphocytic Leukemia (ALL); Drug development and novel clinical trials; Translational science

Read More

Kathleen Boris-Lawrie, PhD

Dr. Boris-Lawrie's laboratory is dedicated to discovering the mRNA regulatory mechanisms necessary for pathogenic retroviruses to replicate and persist. Because retroviruses are dependent on ubiquitous cellular processes, they provide a tractable microcosm to elucidate principles and mechanisms.

Read More

Jonathan Butchar, PhD

Monocytes / macrophages can engulf or even directly kill antibody-coated tumor cells, and this is mediated largely through Fc-gamma receptors. These cells can also respond to pathogens such as bacteria or viruses by activation of Toll-like receptors.

Read More

John Byrd, MD

Dr. Byrd’s research accomplishments relate best to work done between the laboratory and clinic (translational work) with several different therapeutic agents active in CLL and related leukemia and lymphoma. As a consequence of Dr. Byrd’s detailed laboratory and clinical work, therapeutic agents.

Read More

Michael Caligiuri, MD

The Caligiuri laboratory has three areas of interest. First is to understand the development and normal role of the body's large granular lymphocytes called natural killer cells , and to exploit their properties in order to develop effective therapies against cancer and immune deficiency.

Read More

Carlos Castro, PhD

Dr. Castro's research interests include: 1) Utilizing engineering approaches combined with nanotechnology and biophysics experimental tools; 2) Characterize and model the physical properties and behaviors of complex biological systems; 3) goals to establish an array of functional DNA

Read More

Beth Christian, MD

Dr. Christian's research interests are in the experimental therapeutics of Non-Hodgkin’s & Hodgkin’s Lymphoma

Read More

Steven Devine, MD

Dr. Devine studies novel therapies involving the transplantation of adult blood-forming stem cells. His clini¬cal research focuses on allogeneic (donor) blood cell transplan¬tation as a treatment for advanced acute myeloid leukemia and myelodysplastic syndrome.

Read More

Yvonne Efebera, MD

The development of osteolytic bone disease in Multiple Myeloma (MM) is the result of increased osteoclastic bone resorption and impairment of osteoblastic bone formation. The Wnt signaling pathway is important for osteoblastic differentiation.

Read More

Ramiro Garzon, MD

My laboratory is interested in discovering the role of non-coding RNAs in normal Blood formation and how these RNAs may cooperate with other protein coding genes during leukemogenesis

Read More

Patrick Green, PhD

The laboratory of Patrick Green is internationally recognized for their contributions to the understanding of the molecular basis of T-lymphocyte transformation and induction of leukemia/lymphoma and neurological disease by the human T-cell leukemia viruses (HTLVs). The Green lab has three areas.

Read More

Michael Grever, MD

Dr. Grever has over 30 years of experience in experimental chemotherapy and drug development for patients with CLL and other hematologic malignancies. Dr. Grever performed the initial phase I studies on purine nucleoside analogs in patients with hematologic malignancies, and conducted one of the.

Read More

H Grimes, PhD

Dr. Grimes was part of a team that first discovered the Growth factor independent-1 transcription factor which controls blood development and cancer, and he has shown that this factor is mutant in children with severe congenital neutropenia (SCN). Children with SCN lack neutrophils, blood.

Read More

Nyla Heerema, PhD

My research centers on chromosomal abnormalities in hematological malignancies. I am particularly involved in research of  chromosome changes in  pediatric acute lymphoblastic leukemia (ALL )  and their clinical significance,  including the use of fluorescence in situ hybridization (FISH)  for.

Read More

Craig Hofmeister, MD

Our research focuses primarily on phase I/II drug development in Multiple Myeloma with a focus on novel drugs. Initial research into the immunodeficiencies of myeloma and its connection with quality of life are just beginning.

Read More

Gang Huang, PhD

Research in Dr. Huang’s laboratory focuses on genetic and epigenetic regulations of blood cell normal development and leukemia. We first demonstrated that AML1/CBFß (a hetero-dimer transcription factor) and Mixed-Lineage Leukemia (MLL) protein (an enzyme which methylates lysine 4 of histone H3.

Read More

Amy Johnson, PhD

Dr. Johnson's research team has ongoing studies examining PI3-kinase and BTK inhibitors as well as cell cycle and autophagy with flavopiridol in the treatment of CLL.

Read More

Jeffrey Jones, MD

Dr. Jones' research interests include experimental therapeutics in Chronic Lympocytic Leukemia (CLL), health services/outcomes, and research in lymphoid malignancies

Read More

Rosa Lapalombella, MD

Dr. Lapalombella's research interest focuses on two major areas: 1) Epigenetic alterations of cancer cells and 2) Development of experimental therapeutics for hematological disease.

Read More

L. James Lee, PhD

Dr. Lee's research interests are in polymer engineering of nanomaterials and nanotechnology with applications to Bio-Micro-Electro-Mechanical Systems (BioMEMS). MEMS emerged from IC manufacturing and is gaining applications in biomedical and optical communications fields.

Read More

David Lucas, PhD

Dr. Lucas' research interests include Pharmacology of novel anti-leukemic agents, role of transcriptional and translational regulation in tumor cell survival and drug resistance

Read More

Guido Marcucci, MD

Dr. Marcucci's research interests include the biology of acute leukemia; drug development in acute leukemia; and the pathogenesis, treatment and prognostic ssessment of acute myeloid leukemia.

Read More

James Mulloy, PhD

Research in the Mulloy Laboratory focuses on using human hematopoietic stem/progenitor cells (HSPC) to model leukemia. The prevailing theory is that acute myeloid leukemia is a stem cell disease.

Read More

Natarajan Muthusamy, DVM, PhD

Dr. Muthusamy's research interests are focused on the following areas: 1) Biological therapies for hematological malignancies with primary focus on acute and chronic leukemia; 2) Development and characterization of clinically relevant animal models of lymphoid malignancies; 3) Targeted delivery of

Read More

Stefan Niewiesk, DVM, PhD

One of the interests of the Niewiesk laboratory is the use of measles vaccine virus as oncolytic therapy to cure T cell leukemias. We use the mouse model of adult T cell leukemia to study the interaction between tumor cells, microenviroment and virus.

Read More

Qishen Pang, PhD

Dr. Pang's lab studies how Fanconi anemia (FA) proteins function to prevent stress-induced apoptosis and clonal evolution of hematopoietic stem cells and progenitors. Dr. Pang aslo works on a project involving the mechanism by which nucleophosmin (NPM) promotes cell proliferation and suppresses.

Read More

Philip Payne, PhD

Dr. Payne’s research portfolio is broadly situated within the OSU Center for IT Innovation in Healthcare (CITIH), where he serves as the primary scientific leader of a group of over twenty researchers, developers, and trainees who are actively supported by a combination of NCRR, NLM, and NCI

Read More

John Perentesis, MD, FAAP

Dr. Perentesis' clinical research focuses on the development of molecularly targeted therapies for pediatric and adolescent cancer. His laboratory program focuses on complementary studies of leukemia biology and pharmacogenetics of childhood cancer therapy.

Read More

A Mitchell Phelps, PhD

Dr. Phelps' expertise is in analytical methodologies and data modeling to study the disposition of novel anti-cancer agents. His lab is involved in both pre-clinical and clinical development of numerous small molecule anti-cancer and immuno-modulatory agents under development here at OSU.

Read More

Pierluigi Porcu, MD

Dr. Porcu's Clinical interests include: Non-Hodgkin’s Lymphomas; Cutaneous T-Cell Lymphomas, Mycosis Fungoides, Sezary Syndrome, T-cell and NK-cell Lymphomas and his research interests include: T-cell and NK-cell lymphomas; Mycosis Fungoides, Sezary Syndrome, EBV-positive lymphomas.

Read More

Deepa Sampath, MD

Dr. Sampath's research interest is in the epigenetics of Lymphoid Malignancies

Read More

Susheela Tridandapani, PhD

Dr. Tridandapani's research examines the molecular mechanisms of innate immune responses to bacterial pathogens and IgG-immune complexes, particularly in the context of monoclonal antibody therapy for cancer.

Read More

Alison Walker, MD

Dr. Walker's research interests are in AML and MDS(Acute Myeloid Leukemia and Myelodysplastic Syndromes)

Read More

Henry Wong, MD

Dr. Wong’s basic research is focused on the pathogenesis of CTCL. The long term goals are to identify unique molecular biomarkers to improve the accuracy for diagnosis of CTCL, monitor response to therapy, and aid the development of novel treatments.

Read More

Jennifer Woyach, MD

Dr. Woyach’s research interests include chronic lymphocytic leukemia and other hematologic malignancies. Her laboratory research focuses on the role of Bruton’s Tyrosine Kinase (BTK) in the development and expansion of CLL as well as therapeutic BTK inhibition in CLL using murine and cellular.

Read More

Pearlly Yan, PhD

Dr. Yan's research uses sequencing approach to interrogate cancer and disease-related methylomes, developing novel sequencing library protocols and custom computation pipeline to capture the methylome at high resolution.

Read More